

# Pediatric Neuro-Oncology Clinical Trials

## National Cancer Institute in Bethesda, Maryland

**CONTACT INFORMATION: Call the Neuro-Oncology Patient Referral Line at 301-402-6298**

Study Title and Basic Eligibility	Treatment Plan
<p><b>Any primary CNS tumor</b> <i>NCI-01-C-0070</i></p> <p>Evaluation of the natural history of patients with CNS tumors</p> <ul style="list-style-type: none"> <li>Patients must have any CNS tumor</li> </ul>	<ul style="list-style-type: none"> <li>Non-pharmacologic treatment protocol</li> <li>Patients will be followed by consult</li> <li>Diagnostic testing may be performed</li> <li>Patients will have opportunity to be screened for treatment protocol</li> </ul>
<p><b>Low grade gliomas, MBL/PNET, Ependymoma</b> <i>NCI-98-C-0074</i></p> <p>Phase II study of intravenous Cereport® (RMP-7) and carboplatin in childhood brain tumors</p> <ul style="list-style-type: none"> <li>Patient must have brain tumor with evidence of progression</li> <li>ECOG performance of 0-2</li> <li>No more than one prior chemotherapy regimen</li> </ul>	<ul style="list-style-type: none"> <li>Patients will receive infusion of Cereport® prior to receiving carboplatin</li> <li>Combination of Cereport® and carboplatin will be given for 2 consecutive days every 28 days for up to 12 cycles or no progressive disease</li> </ul>
<p><b>Vaccine for glioblastoma following RT</b> <i>NCI-01-C-0176</i></p> <p>Immunization of HLA-A*0201 patients with metastatic cancer using a modified epitope from the ESO-1 antigen</p> <ul style="list-style-type: none"> <li>&gt; 16 years old</li> <li>Not currently on steroids</li> <li>No systemic therapy in past 3 weeks</li> <li>Patients must not have progressive disease following radiation therapy</li> </ul>	<ul style="list-style-type: none"> <li>Patients will be evaluated at NCI post-radiation therapy</li> <li>Patients will be immunized with immunogenic peptide ESO-1 from telomerase protein</li> <li>Peptide will be administered either every week for 10 cycles, every 3 weeks for 4 cycles, or 4x/week every 3 weeks for 4 cycles</li> </ul>
<p><b>Patients with brain tumors OR patients receiving neurotoxic therapy</b> <i>NCI-99-C-0088</i></p> <p>Nuclear magnetic resonance spectroscopic (NMRS) imaging of the brain in patients receiving neurotoxic therapy</p> <ul style="list-style-type: none"> <li>Patients with brain tumors</li> <li>Patients with any tumor type who have received potential neurotoxic therapies (radiation, chemotherapy, intrathecal chemotherapy)</li> <li>Patients with clinical neurotoxicity that is presumed to be treatment related</li> <li>Able to undergo imaging studies</li> <li>No metallic implants</li> <li>No history of severe reaction to contrast agents</li> </ul> <p><i>NCI 97-C-0093</i> A Pilot Study of <sup>1</sup>H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients with Primary and Metastatic Brain Tumors</p> <ul style="list-style-type: none"> <li>≤21 years of age</li> <li>Entered on a NCI treatment protocol or Natural History protocol</li> <li>Histologically confirmed primary or metastatic brain tumor (unless brainstem)</li> <li>Able to undergo MR imaging</li> </ul>	<ul style="list-style-type: none"> <li>NMRS studies will be performed at any or all of the following times: prior to therapy, during therapy, and upon completion of therapy</li> <li>Neurotoxicity will be evaluated by neuropsychological testing</li> <li>Patients will have opportunity to be screened for treatment protocol</li> </ul> <ul style="list-style-type: none"> <li>NMRS performed before, during, and/or after therapy</li> </ul>

### **Pontine Glioma post Radiation Therapy**

NCI 02-C-0193

- |   |   |
|---|---|
| <ul style="list-style-type: none"><li>• <math>\leq 21</math> years of age</li><li>• diffuse pontine glioma</li><li>• Patients must have received radiation therapy</li><li>• Radiation completed 2-10 weeks prior to starting PEG-Intron</li><li>• ECOG of 0-3</li><li>• Stable or decreasing steroids <math>\geq 1</math> week prior to starting PEG-Intron</li><li>• No prior chemotherapy or radiosensitizers</li><li>• No neurofibromatosis-1</li></ul> | <ul style="list-style-type: none"><li>• Weekly subcutaneous PEG-Intron</li><li>• Pre-medication with acetaminophen</li><li>• Imaging (MRI, NMRS, perfusion, etc) at NCI</li></ul> |
|---|---|